Predicted to enable phosphatidylinositol-3,4-bisphosphate binding activity; phosphatidylinositol-3,5-bisphosphate binding activity; and phosphatidylinositol-3-phosphate binding activity. Predicted to be involved in actin cytoskeleton organization and positive regulation of plasma membrane bounded cell projection assembly. Predicted to act upstream of or within positive regulation of cell projection organization. Predicted to be located in membrane. Predicted to be active in plasma membrane. Orthologous to human PLEK2 (pleckstrin 2).
RGD Description
Predicted to enable phosphatidylinositol-3,4-bisphosphate binding activity; phosphatidylinositol-3,5-bisphosphate binding activity; and phosphatidylinositol-3-phosphate binding activity. Predicted to be involved in actin cytoskeleton organization and positive regulation of plasma membrane bounded cell projection assembly. Predicted to act upstream of or within positive regulation of cell projection organization. Predicted to be located in membrane. Predicted to be active in plasma membrane. Orthologous to human PLEK2 (pleckstrin 2); INTERACTS WITH (+)-schisandrin B; 2,3,7,8-Tetrachlorodibenzofuran; 2,4-dinitrotoluene.